688315.SS
Price:
$14.05
Market Cap:
$5.69B
Novogene Co., Ltd. provides genomic services and solutions worldwide. The company offers genomic solutions, such as human genome sequencing, gene regulation, single cell sequencing, animal and plant solutions, and microbial genome sequencing; and cancer genomic profiling, whole exome sequencing, and FFPE RNA sequencing, as well as clinical-grade whole exome sequencing services. It also provides NovoFocus, a next-generation sequencing based companion diagnostic assay for PARP inhibitor therapies; and NovoNeoantigen, a bioinformatics pipeline for the identification of cancer neoantigens with whole exome sequencing and whole transcriptome sequencing data from paired tumor-normal samples. Novoge...[Read more]
Industry
Biotechnology
IPO Date
2021-04-13
Stock Exchange
SHH
Ticker
688315.SS
According to Novogene Co., Ltd.’s latest financial reports and current stock price. The company's current PE Ratio is 28.67. This represents a change of 0.87% compared to the average of 28.42 of the last 4 quarters.
The mean historical PE Ratio of Novogene Co., Ltd. over the last ten years is 135.71. The current 28.67 PE Ratio has changed 2.01% with respect to the historical average. Over the past ten years (40 quarters), 688315.SS's PE Ratio was at its highest in in the March 2018 quarter at 195.71. The PE Ratio was at its lowest in in the June 2020 quarter at -185.67.
Average
135.71
Median
88.27
Minimum
26.04
Maximum
442.36
Discovering the peaks and valleys of Novogene Co., Ltd. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 212.78%
Maximum Annual PE Ratio = 442.36
Minimum Annual Increase = -81.78%
Minimum Annual PE Ratio = 26.04
Year | PE Ratio | Change |
---|---|---|
2024 | 26.04 | -50.91% |
2023 | 53.05 | -10.98% |
2022 | 59.59 | -18.81% |
2021 | 73.39 | -75.54% |
2020 | 300.10 | 212.78% |
2019 | 95.95 | -5.45% |
2018 | 101.48 | -18.52% |
2017 | 124.55 | 54.55% |
2016 | 80.59 | -81.78% |
The current PE Ratio of Novogene Co., Ltd. (688315.SS) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
46.23
5-year avg
102.43
10-year avg
135.71
Novogene Co., Ltd.’s PE Ratio is greater than New Horizon Health Limited (-68.94), greater than Oxford Nanopore Technologies plc (-8.21),
Company | PE Ratio | Market cap |
---|---|---|
-68.94 | $6.32B | |
-8.21 | $1.23B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Novogene Co., Ltd. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Novogene Co., Ltd. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Novogene Co., Ltd.'s PE Ratio?
How is the PE Ratio calculated for Novogene Co., Ltd. (688315.SS)?
What is the highest PE Ratio for Novogene Co., Ltd. (688315.SS)?
What is the 3-year average PE Ratio for Novogene Co., Ltd. (688315.SS)?
What is the 5-year average PE Ratio for Novogene Co., Ltd. (688315.SS)?
How does the current PE Ratio for Novogene Co., Ltd. (688315.SS) compare to its historical average?